HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ferrarese, C. Articles by Frattola, L. Search for Related Content PubMed PubMed Citation Articles by Ferrarese, C. Articles by Frattola, L. Related Collections HIV HIV dementia

Increased glutamate in CSF and plasma of patients with HIV dementia

From the Department of Neurology (Drs. Ferrarese, Aliprandi, Tremolizzo, Stazani, and Frattola), University of Milano–Bicocca; and Department of Infectious Diseases (Drs. De Micheli and Dolara), St. Gerardo Hospital, Monza, Italy.

Address correspondence and reprint requests to Dr. C. Ferrarese, Department of Neurology, University of Milano–Bicocca, San Gerardo Hospital, via Donizetti, 106-20052 Monza (MI), Italy; e-mail: carlo.ferrarese{at}unimib.it

Background:— Experimental evidence suggests that excitotoxicity might play a major role in HIV-induced neurodegeneration. However, few studies have investigated the role of endogenous glutamate in patients with HIV dementia.

Objective:— To analyze CSF and plasma glutamate levels in 30 patients with AIDS with different dementia severity compared with 10 patients with other neurologic disorders, 11 healthy control subjects, and 10 patients with Alzheimer-type dementia.

Methods:— CSF and plasma glutamate levels were measured by reverse-phase high-performance liquid chromatography followed by fluorometric analysis.

Results:— Glutamate CSF levels were increased fivefold in the patients with HIV vs normal control subjects (p = 0.001), patients with Alzheimer-type dementia (p < 0.0001), and patients with other neurologic disorders (p < 0.01). CSF glutamate levels were also related to the degree of dementia (p < 0.02) and brain atrophy (p < 0.002). Plasma levels were also higher in the patients with HIV (p < 0.0001) but did not correlate with either clinical or imaging features.

Conclusion:— Increased CSF glutamate may originate within the CNS and may play a pathogenetic role in HIV dementia, thus supporting the treatment of these patients with glutamate receptor antagonists.

This article has been cited by other articles:

				R. Pacheco, H. Oliva, J. M. Martinez-Navio, N. Climent, F. Ciruela, J. M. Gatell, T. Gallart, J. Mallol, C. Lluis, and R. Franco Glutamate Released by Dendritic Cells as a Novel Modulator of T Cell Activation J. Immunol., November 15, 2006; 177(10): 6695 - 6704. [Abstract] [Full Text] [PDF]

				C. Poulopoulou, I. Markakis, P. Davaki, C. Nikolaou, A. Poulopoulos, E. Raptis, and D. Vassilopoulos Modulation of Voltage-Gated Potassium Channels in Human T Lymphocytes by Extracellular Glutamate Mol. Pharmacol., March 1, 2005; 67(3): 856 - 867. [Abstract] [Full Text] [PDF]

				L. A. Boven, N. Vergnolle, S. D. Henry, C. Silva, Y. Imai, J. Holden, K. Warren, M. D. Hollenberg, and C. Power Up-Regulation of Proteinase-Activated Receptor 1 Expression in Astrocytes During HIV Encephalitis J. Immunol., March 1, 2003; 170(5): 2638 - 2646. [Abstract] [Full Text] [PDF]

				M. G. Espey, A. S. Basile, R. K. Heaton, R. J. Ellis, A. Aliprandi, M. Longoni, L. Tremolizzo, and C. Ferrarese Increased glutamate in CSF and plasma of patients with HIV dementia Neurology, May 14, 2002; 58(9): 1439 - 1440. [Full Text] [PDF]